Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: An overview of new derivatives of natural combretastatin A-4

Current Medicinal Chemistry

Volumn 18, Issue 20, 2011, Pages 3035-3081

  Marrelli, M ^a   Conforti, F ^a   Statti, G A ^a   Cachet, X ^b   Michel, S ^b   Tillequin, F ^b   Menichini, F ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Combretastatin A 4; Combretastatin analogs; Structure activity relationships; Tubulin; Vascular disrupting agents

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; COLCHICINE; COMBRETASTATIN; COMBRETASTATIN A1; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A2; COMBRETASTATIN A3; COMBRETASTATIN A4; COMBRETASTATIN A4 DERIVATIVE; COMBRETASTATIN A4 PHOSPHATE; COMBRETASTATIN A5; DISCODERMOLIDE; ESTRAMUSTINE; LAULIMALIDE; MICROTUBULE DAMAGING AGENT; MITOFLAXONE; N ACETYLCOLCHINOL PHOSPHATE; OMBRABULIN; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; VASCULAR TARGETING AGENT; VINBLASTINE; VINCA ALKALOID;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER PAIN; CELL CYCLE ARREST; CLINICAL TRIAL (TOPIC); CYTOSKELETON; CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HUMAN; MICROTUBULE ASSEMBLY; NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBRETUM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79960006369     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796391642     Document Type: Review

References (103)

1. Cragg, G. M.; Newman, D. J., Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100(1-2), 72-79. (Pubitemid 41073525)
2. Banerjee, S.; Wang, Z.; Mohammad, M.; Sarkar, F. H.; Mohammad, R. M., Efficacy of selected natural products as therapeutic agents against cancer. J. Nat. Prod., 2008, 71(3), 492-496. (Pubitemid 351549382)
3. Yang, Z. Q., Synthesis and in vitro biological activity evaluation of the derivatives of combretastatin A-4. Lett. Drug Des. Discovery, 2006, 3(8), 544-546.
4. Chen, G.; Horsman, M. R.; Pedersen, M.; Pang, Q.; Stodkilde-Jorgensen, H.,. The effect of combretastatin A4 disodium phosphate and 5, 6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours. Acta. Oncol., 2008, 47(6), 1071-1076.
5. Griggs, J.; Metcalfe, J. C.; Hesketh, R., Targeting tumour vasculature: the development of combretastatin A4. Lancet. Oncol., 2001, 2(2), 82-87. (Pubitemid 33585919)
6. Grosios, K.; Holwell, S. E.; McGown, A. T.; Pettit, G. R.; Bibby, M. C., In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer., 1999, 81(8), 1318-1327.
7. Salmon, B. A.; Siemann, D. W., Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int. J. Radiat. Oncol. Biol. Phys., 2007, 68(1), 211-217. (Pubitemid 46589857)
8. Salmon, B. A.; Salmon, H. W.; Siemann, D. W., Monitoring the treatment efficacy of the vascular disrupting agent CA4P. Eur. J. Cancer., 2007, 43(10), 1622-1629. (Pubitemid 46891803)
9. West, C. M.; Price, P., Combretastatin A4 phosphate. Anti-Cancer Drugs, 2004, 15(3), 179-187. (Pubitemid 38429409)
10. Thorpe, P. E.; Chaplin, D. J.; Blakey, D. C., The first international conference on vascular targeting: meeting overview. Cancer. Res., 2003, 63(5), 1144-1147. (Pubitemid 36278450)
11. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D., Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia, 1989, 45(2), 209-211. (Pubitemid 19062390)
12. Kerr, D. J.; Hamel, E.; Jung, M. K.; Flynn, B. L., The concise synthesis of chalcone, indanone and indenone analogues of combretastatin A4. Bioorg. Med. Chem., 2007, 15(9), 3290-3298. (Pubitemid 46505268)
13. Bhattacharyya, B.; Panda, D.; Gupta, S.; Banerjee, M., Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med. Res. Rev., 2008, 28(1), 155-183. (Pubitemid 350274963)
14. Pinney, K. G.; Mejia, M. P.; Villalobos, V. M.; Rosenquist, B. E.; Pettit, G. R.; Verdier-Pinard, P.; Hamel, E., Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorg. Med. Chem., 2000, 8(10), 2417-2425.
15. Nogales, E.; Wolf, S. G.; Downing, K. H., Structure of the alpha beta tubulin dimer by electron crystallography. Nature, 1998, 391(6663), 199-203. (Pubitemid 28092482)
16. Hammond, J. W.; Cai, D. W.; Verhey, K. J., Tubulin modifications and their cellular functions. Curr. Opin. Cell Biol., 2008, 20(1), 71-76.
17. Gardner, M. K.; Hunt, A. J.; Goodson, H. V.; Odde, D. J., Microtubule assembly dynamics: new insights at the nanoscale. Curr. Opin. Cell Biol., 2008, 20(1), 64-70.
18. Li, P. K.; Xiao, Z.; Hu, Z.; Pandit, B.; Sun, Y.; Sackett, D. L.; Werbovetz, K.; Lewis, A.; Johnsamuel, J., Conformationally restricted analogs of Combretastatin A-4 derived from SU5416. Bioorg. Med. Chem. Lett., 2005, 15(24), 5382-5385. (Pubitemid 41562954)
19. Farce, A.; Loge, C.; Gallet, S.; Lebegue, N.; Carato, P.; Chavatte, P.; Berthelot, P.; Lesieur, D., Docking study of ligands into the colchicine binding site of tubulin. J. Enzyme Inhib. Med. Chem., 2004, 19(6), 541-547. (Pubitemid 40057744)
20. Howard, J.; Hyman, A. A., Dynamics and mechanics of the microtubule plus end. Nature, 2003, 422(6933), 753-758. (Pubitemid 36514118)
21. Maya, A. B.; del Rey, B.; Lamamie de Clairac, R. P.; Caballero, E.; Barasoain, I.; Andreu, J. M.; Medarde, M., Design, synthesis and cytotoxic activities of naphthyl analogues of combretastatin A-4. Bioorg. Med. Chem. Lett., 2000, 10(22), 2549-2551.
22. Rappl, C.; Barbier, P.; Bourgarel-Rey, V.; Gregoire, C.; Gilli, R.; Carre, M.; Combes, S.; Finet, J. P.; Peyrot, V., Interaction of 4-arylcoumarin analogues of combretastatins with microtubule network of HBL100 cells and binding to tubulin. Biochemistry, 2006, 45(30), 9210-9218. (Pubitemid 44156384)
23. Cenciarelli, C.; Tanzarella, C.; Vitale, I.; Pisano, C.; Crateri, P.; Meschini, S.; Arancia, G.; Antoccia, A., The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis, 2008, 13(5), 659-669.
24. Quan, H.; Xu, Y.; Lou, L., p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. In. t J. Cancer, 2008, 122(8), 1730-1737. (Pubitemid 351413418)
25. Ducki, S.; Mackenzie, G.; Lawrence, N. J.; Snyder, J. P., Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly. J. Med. Chem., 2005, 48(2), 457-465. (Pubitemid 40139788)
26. Folkman, J., Angiogenesis inhibitors: a new class of drugs. Cancer Biol. Ther., 2003, 2(4 Suppl 1), S127-133.
27. Kanthou, C.; Tozer, G. M., Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int. J. Exp. Pathol., 2009, 90(3), 284-294.
28. Siemann, D. W.; Chaplin, D. J.; Horsman, M. R., Vascular-targeting therapies for treatment of malignant disease. Cancer, 2004, 100(12), 2491-2499. (Pubitemid 38715753)
29. van Heeckeren, W. J.; Bhakta, S.; Ortiz, J.; Duerk, J.; Cooney, M. M.; Dowlati, A.; McCrae, K.; Remick, S. C., Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J. Clin. Oncol., 2006, 24(10), 1485-1488. (Pubitemid 46638767)
30. Baguley, B. C.; Ching, L. M., DMXAA: an antivascular agent with multiple host responses. Int. J. Radiat. Oncol. Biol. Phys., 2002, 54(5), 1503-1511. (Pubitemid 35380056)
31. Philpott, M.; Baguley, B. C.; Ching, L. M., Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5, 6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol., 1995, 36(2), 143-148.
32. Siemann, D. W.; Mercer, E.; Lepler, S.; Rojiani, A. M., Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer, 2002, 99(1), 1-6. (Pubitemid 34273190)
33. Kanthou, C.; Tozer, G. M., The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood, 2002, 99(6), 2060-2069. (Pubitemid 34525489)
34. Davis, P. D.; Tozer, G. M.; Naylor, M. A.; Thomson, P.; Lewis, G.; Hill, S. A., Enhancement of vascular targeting by inhibitors of nitric oxide synthase. Int. J. Radiat. Oncol. Biol. Phys., 2002, 54(5), 1532-1536. (Pubitemid 35380060)
35. Nam, N. H., Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem., 2003, 10(17), 1697-1722.
36. Odlo, K.; Hentzen, J.; dit Chabert, J. F.; Ducki, S.; Gani, O. A. B. S. M.; Sylte, I.; Skrede, M.; Florenes, V. A.; Hansen, T. V., 1, 5-disubstituted 1, 2, 3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin. Bioorg. Med. Chem., 2008, 16(9), 4829-4838. (Pubitemid 351625899)
37. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A., Medicinal chemistry of combretastatin A4: present and future directions. J. Med. Chem., 2006, 49(11), 3033-3044. (Pubitemid 43830499)
38. Orsini, F.; Pelizzoni, F.; Bellini, B.; Miglierini, G., Synthesis of biologically active polyphenolic glycosides (combretastatin and resveratrol series). Carbohydr. Res., 1997, 301(3-4), 95-109. (Pubitemid 27272234)
39. Hall, J. J.; Sriram, M.; Strecker, T. E.; Tidmore, J. K.; Jelinek, C. J.; Kumar, G. D.; Hadimani, M. B.; Pettit, G. R.; Chaplin, D. J.; Trawick, M. L.; Pinney, K. G., Design, synthesis, biochemical, and biological evaluation of nitrogencontaining trifluoro structural modifications of combretastatin A-4. Bioorg. Med. Chem. Lett., 2008, 18(18), 5146-5149.
40. Kaffy, J.; Pontikis, R.; Florent, J. C.; Monneret, C., Synthesis and biological evaluation of vinylogous combretastatin A-4 derivatives. Org. Biomol. Chem., 2005, 3(14), 2657-2660. (Pubitemid 41068506)
41. Kaffy, J.; Pontikis, R.; Carrez, D.; Croisy, A.; Monneret, C.; Florent, J. C., Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation. Bioorg. Med. Chem., 2006, 14(12), 4067-4077.
42. Pettit, G. R.; Grealish, M. P.; Herald, D. L.; Boyd, M. R.; Hamel, E.; Pettit, R. K., Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug. J. Med. Chem., 2000, 43(14), 2731-2737. (Pubitemid 30463921)
43. Chaudhary, A.; Pandeya, S. N.; Kumar, P.; Sharma, P. P.; Gupta, S.; Soni, N.; Verma, K. K.; Bhardwaj, G., Combretastatin a-4 analogs as anticancer agents. Mini Rev. Med. Chem., 2007, 7(12), 1186-1205. (Pubitemid 350303084)
44. Lawrence, N. J.; Hepworth, L. A.; Rennison, D.; McGown, A. T.; Hadfield, J. A., Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4. J. Fluorine Chem., 2003, 123(1), 101-108.
45. Nabha, S. M.; Mohammad, R. M.; Dandashi, M. H.; Coupaye-Gerard, B.; Aboukameel, A.; Pettit, G. R.; Al-Katib, A. M., Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly (ADP-ribose) polymerase cleavage. Clin. Cancer Res., 2002, 8(8), 2735-2741. (Pubitemid 34856363)
46. Kador, P. F.; Blessing, K.; Randazzo, J.; Makita, J.; Wyman, M., Evaluation of the vascular targeting agent combretastatin a-4 prodrug on retinal neovascularization in the galactose-fed dog. J. Ocul. Pharmacol. Ther., 2007, 23(2), 132-142. (Pubitemid 46642155)
47. Griggs, J.; Skepper, J. N.; Smith, G. A.; Brindle, K. M.; Metcalfe, J. C.; Hesketh, R., Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am. J. Pathol., 2002, 160(3), 1097-1103. (Pubitemid 34224596)
48. Griggs, J.; Hesketh, R.; Smith, G. A.; Brindle, K. M.; Metcalfe, J. C.; Thomas, G. A.; Williams, E. D., Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br. J. Cancer, 2001, 84(6), 832-835. (Pubitemid 32275659)
49. Pettit, G. R.; Rhodes, M. R., Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug. Des., 1998, 13(3), 183-191. (Pubitemid 28188203)
50. Adams, J.; Elliott, P. J., New agents in cancer clinical trials. Oncogene, 2000, 19(56), 6687-6692. (Pubitemid 32197709)
51. Rustin, G. J.; Galbraith, S. M.; Anderson, H.; Stratford, M.; Folkes, L. K.; Sena, L.; Gumbrell, L.; Price, P. M., Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol., 2003, 21(15), 2815-2822. (Pubitemid 46621828)
52. Gaya, A.; Daley, F.; Taylor, N. J.; Tozer, G.; Qureshi, U.; Padhani, A.; Pedley, R. B.; Begent, R.; Wellsted, D.; Stirling, J. J.; Rustin, G., Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study. Br. J. Cancer, 2008, 99(2), 321-326.
53. Tozer, G. M.; Prise, V. E.; Wilson, J.; Cemazar, M.; Shan, S.; Dewhirst, M. W.; Barber, P. R.; Vojnovic, B.; Chaplin, D. J., Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res., 2001, 61(17), 6413-6422. (Pubitemid 32785286)
54. Stevenson, J. P.; Rosen, M.; Sun, W.; Gallagher, M.; Haller, D. G.; Vaughn, D.; Giantonio, B.; Zimmer, R.; Petros, W. P.; Stratford, M.; Chaplin, D.; Young, S. L.; Schnall, M.; O'Dwyer, P. J., Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol., 2003, 21(23), 4428-4438. (Pubitemid 46621821)
55. Simoni, D.; Romagnoli, R.; Baruchello, R.; Rondanin, R.; Grisolia, G.; Eleopra, M.; Rizzi, M.; Tolomeo, M.; Giannini, G.; Alloatti, D.; Castorina, M.; Marcellini, M.; Pisano, C., Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity. J. Med. Chem., 2008, 51(19), 6211-6215.
56. Chaplin, D. J.; Hill, S. A., The development of combretastatin A4 phosphate as a vascular targeting agent. Int. J. Radiat. Oncol. Biol. Phys., 2002, 54(5), 1491-1496. (Pubitemid 35380054)
57. Kirwan, I. G.; Loadman, P. M.; Swaine, D. J.; Anthoney, D. A.; Pettit, G. R.; Lippert, J. W., 3rd; Shnyder, S. D.; Cooper, P. A.; Bibby, M. C., Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin. Cancer Res., 2004, 10(4), 1446-1453. (Pubitemid 38365240)
58. Michels, S.; Schmidt-Erfurth, U.; Rosenfeld, P. J., Promising new treatments for neovascular age-related macular degeneration. Expert. Opin. Investig. Drugs, 2006, 15(7), 779-793.
59. Pettit, G. R.; Minardi, M. D.; Hogan, F.; Price, P. M., An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins. J. Nat. Prod., 2010, 73(3), 399-403.
60. Dowlati, A.; Robertson, K.; Cooney, M.; Petros, W. P.; Stratford, M.; Jesberger, J.; Rafie, N.; Overmoyer, B.; Makkar, V.; Stambler, B.; Taylor, A.; Waas, J.; Lewin, J. S.; McCrae, K. R.; Remick, S. C., A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res., 2002, 62(12), 3408-3416. (Pubitemid 34651387)
61. Dziba, J. M.; Marcinek, R.; Venkataraman, G.; Robinson, J. A.; Ain, K. B., Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid, 2002, 12(12), 1063-1070. (Pubitemid 36114813)
62. Siemann, D. W.; Shi, W., Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res., 2008, 28(4 B), 2027-2031.
63. James, C.; Pettit, G. R.; Nielsen, O. F.; Jayakumar, V. S.; Joe, I. H., Vibrational spectra and ab initio molecular orbital calculations of the novel anti-cancer drug combretastatin A-4 prodrug. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2008, 70(5), 1208-1216.
64. Pettit, G. R.; Singh, S. B.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Schmidt, J. M.; Hogan, F., Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6 (1a). J. Med. Chem., 1995, 38(10), 1666-1672.
65. Lara-Ochoa F.; Espinosa-Pérez, G., A new synthesis of combretastatins A-4 and AVE-8062A. Tetrahedron Lett., 2007, 48(39), 7007.
66. Harrowven, D. C.; Guy, I. L.; Howell, J. C.; Packham, G., The Synthesis of a Combretastatin A-4 Based Library and Discovery of New Cooperative ortho-Effects in Wittig Reactions Leading to (Z)-Stilbenes. Synlett, 2006, 2006(18), 2977.
67. Robinson, J. E.; Taylor, R. J., A Ramberg-Backlund route to the stilbenoid anti-cancer agents combretastatin A-4 and DMU-212. Chem. Commun. (Camb), 2007(16), 1617-1619. (Pubitemid 46813956)
68. Camacho-Davila, A. A., Kumada-Corriu Cross Coupling Route to the Anti-Cancer Agent Combretastatin A-4. Synth. Commun., 2008, 38(21), 11.
69. Lee, L.; Davis, R.; Vanderham, J.; Hills, P.; Mackay, H.; Brown, T.; Mooberry, S. L.; Lee, M., 1, 2, 3, 4-Tetrahydro-2-thioxopyrimidine analogs of combretastatin-A4. Eur. J. Med. Chem., 2008, 43(9), 2011-2015.
70. Johnson, M.; Younglove, B.; Lee, L.; LeBlanc, R.; Holt, H.; Hills, P.; Mackay, H.; Brown, T.; Mooberry, S. L.; Lee, M., Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. Bioorg. Med. Chem. Lett., 2007, 17(21), 5897-5901. (Pubitemid 47446212)
71. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; Hannick, S. M.; Gherke, L.; Credo, R. B.; Hui, Y. H.; Marsh, K.; Warner, R.; Lee, J. Y.; Zielinski-Mozng, N.; Frost, D.; Rosenberg, S. H.; Sham, H. L., Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structureactivity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem., 2002, 45(8), 1697-1711. (Pubitemid 34293536)
72. Ohsumi, K.; Hatanaka, T.; Fujita, K.; Nakagawa, R.; Fukuda, Y.; Nihei, Y.; Suga, Y.; Morinaga, Y.; Akiyama, Y.; Tsuji, T., Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg. Med. Chem. Lett., 1998, 8(22), 3153-3158. (Pubitemid 28551638)
73. Nam, N. H.; Kim, Y.; You, Y. J.; Hong, D. H.; Kim, H. M.; Ahn, B. Z., Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues. Bioorg. Med. Chem. Lett., 2002, 12(15), 1955-1958. (Pubitemid 34756457)
74. Kim, Y.; Nam, N. H.; You, Y. J.; Ahn, B. Z., Synthesis and cytotoxicity of 3, 4-diaryl-2 (5H)-furanones. Bioorg. Med. Chem. Lett., 2002, 12(4), 719-722.
75. Nam, N. H.; Kim, Y.; You, Y. J.; Hong, D. H.; Kim, H. M.; Ahn, B. Z., Combretoxazolones: synthesis, cytotoxicity and antitumor activity. Bioorg. Med. Chem. Lett., 2001, 11(23), 3073-3076. (Pubitemid 33063632)
76. Singh, R.; Kaur, H., Advances in Synthetic Approaches for the Preparation of Combretastatin-Based Anti-Cancer Agents. Synthesis, 2009, 2009(15), 21.
77. Brown, T.; Holt, H.; Lee, M., Synthesis of Biologically Active Heterocyclic Stilbene and Chalcone Analogs of Combretastatin. Top Heterocycl. Chem., 2006, 2006(2), 51.
78. Das, B. C.; Mahalingam, S. M.; Evans, T., Design and synthesis of novel pinacolylboronate containing combretastatin 'antimitotic agent' analogues. Tetrahedron Lett., 2009, 50(25), 3031-3034.
79. Coccetti, P.; Montano, G.; Lombardo, A.; Tripodi, F.; Orsini, F.; Pagliarin, R., Synthesis and biological evaluation of combretastatin analogs as cell cycle inhibitors of the G1 to S transition in Saccharomyces cerevisiae. Bioorg. Med. Chem. Lett., 2010, 20(9), 2780-2784.
80. Fortin, S.; Moreau, E.; Lacroix, J.; Teulade, J. C.; Patenaude, A.; R, C. G., N-Phenyl-N'-(2-chloroethyl) urea analogues of combretastatin A-4: Is the N-phenyl-N'-(2-chloroethyl) urea pharmacophore mimicking the trimethoxy phenyl moiety? Bioorg. Med. Chem. Lett., 2007, 17(7), 2000-2004. (Pubitemid 46389583)
81. Nguyen, T. L.; McGrath, C.; Hermone, A. R.; Burnett, J. C.; Zaharevitz, D. W.; Day, B. W.; Wipf, P.; Hamel, E.; Gussio, R., A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J. Med. Chem., 2005, 48(19), 6107-6116. (Pubitemid 41324618)
82. Mousset, C.; Giraud, A.; Provot, O.; Hamze, A.; Bignon, J.; Liu, J. M.; Thoret, S.; Dubois, J.; Brion, J. D.; Alami, M., Synthesis and antitumor activity of benzils related to combretastatin A-4. Bioorg. Med. Chem. Lett., 2008, 18(11), 3266-3271. (Pubitemid 351728092)
83. Tanpure, R. P.; Harkrider, A. R.; Strecker, T. E.; Hamel, E.; Trawick, M. L.; Pinney, K. G., Application of the McMurry coupling reaction in the synthesis of tri-and tetra-arylethylene analogues as potential cancer chemotherapeutic agents. Bioorg. Med. Chem., 2009, 17(19), 6993-7001.
84. Ducki, S.; Rennison, D.; Woo, M.; Kendall, A.; Chabert, J. F.; McGown, A. T.; Lawrence, N. J., Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. Bioorg. Med. Chem., 2009, 17(22), 7698-7710.
85. Kong, Y.; Wang, K.; Edler, M. C.; Hamel, E.; Mooberry, S. L.; Paige, M. A.; Brown, M. L., A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg. Med. Chem., 2010, 18(2), 971-977.
86. Alloatti, D.; Giannini, G.; Cabri, W.; Lustrati, I.; Marzi, M.; Ciacci, A.; Gallo, G.; Tinti, M. O.; Marcellini, M.; Riccioni, T.; Guglielmi, M. B.; Carminati, P.; Pisano, C., Synthesis and biological activity of fluorinated combretastatin analogues. J. Med. Chem., 2008, 51(9), 2708-2721. (Pubitemid 351620793)
87. Ty, N.; Kaffy, J.; Arrault, A.; Thoret, S.; Pontikis, R.; Dubois, J.; Morin-Allory, L.; Florent, J. C., Synthesis and biological evaluation of cis-locked vinylogous combretastatin-A4 analogues: derivatives with a cyclopropylvinyl or a cyclopropyl-amide bridge. Bioorg. Med. Chem. Lett., 2009, 19(5), 1318-1322.
88. Cafici, L.; Pirali, T.; Condorelli, F.; Del Grosso, E.; Massarotti, A.; Sorba, G.; Canonico, P. L.; Tron, G. C.; Genazzani, A. A., Solution-phase parallel synthesis and biological evaluation of combretatriazoles. J. Comb. Chem., 2008, 10(5), 732-740.
89. Pirali, T.; Busacca, S.; Beltrami, L.; Imovilli, D.; Pagliai, F.; Miglio, G.; Massarotti, A.; Verotta, L.; Tron, G. C.; Sorba, G.; Genazzani, A. A., Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents. J. Med. Chem., 2006, 49(17), 5372-5376. (Pubitemid 44260231)
90. Wu, M. J.; Sun, Q. M.; Yang, C. H.; Chen, D. D.; Ding, J.; Chen, Y.; Lin, L. P.; Xie, Y. Y., Synthesis and activity of Combretastatin A-4 analogues: 1, 2, 3-thiadiazoles as potent antitumor agents. Bioorg. Med. Chem. Lett., 2007, 17(4), 869-873. (Pubitemid 46177634)
91. Liu, Z. Y.; Wang, Y. M.; Li, Z. R.; Jiang, J. D.; Boykin, D. W., Synthesis and anticancer activity of novel 3, 4-diarylthiazol-2(3H)-ones (imines). Bioorg. Med. Chem. Lett., 2009, 19 (19), 5661-5664.
92. Duan, J. X.; Cai, X. H.; Meng, F. Y.; Lan, L.; Hart, C.; Matteucci, M., Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles. J. Med. Chem., 2007, 50(5), 1001-1006. (Pubitemid 46394002)
93. Ty, N.; Dupeyre, G.; Chabot, G. G.; Seguin, J.; Tillequin, F.; Scherman, D.; Michel, S.; Cachet, X., Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3', 4', 5'-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents. Bioorg. Med. Chem., 2008, 16(15), 7494-7503.
94. Sun, C. M.; Lin, L. G.; Yu, H. J.; Cheng, C. Y.; Tsai, Y. C.; Chu, C. W.; Din, Y. H.; Chau, Y. P.; Don, M. J., Synthesis and cytotoxic activities of 4, 5-diarylisoxazoles. Bioorg. Med. Chem. Lett., 2007, 17(4), 1078-1081.
95. Biersack, B.; Effenberger, K.; Schobert, R.; Ocker, M., Oxazole-bridged combretastatin A analogues with improved anticancer properties. ChemMedChem, 2010, 5(3), 420-427.
96. Bellina, F.; Cauteruccio, S.; Monti, S.; Rossi, R., Novel imidazole-based combretastatin A-4 analogues: Evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. Bioorg. Med. Chem. Lett., 2006, 16(22), 5757-5762. (Pubitemid 44486746)
97. Nien, C. Y.; Chen, Y. C.; Kuo, C. C.; Hsieh, H. P.; Chang, C. Y.; Wu, J. S.; Wu, S. Y.; Liou, J. P.; Chang, J. Y., 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J. Med. Chem., 2010, 53(5), 2309-2313.
98. Arthuis, M.; Pontikis, R.; Florent, J. C., Tandem Heck-Suzuki-Miyaura reaction: Application to the synthesis of constrained analogues of combretastatin A-4. Tetrahedron Lett., 2007, 48(36), 6397-6400. (Pubitemid 47211225)
99. Mateo, C.; Alvarez, R.; Perez-Melero, C.; Pelaez, R.; Medarde, M., Conformationally restricted macrocyclic analogues of combretastatins. Bioorg. Med. Chem. Lett., 2007, 17(22), 6316-6320. (Pubitemid 47552811)
100. Kessler, T.; Bayer, M.; Schwoppe, C.; Liersch, R.; Mesters, R. M.; Berdel, W. E. In Angiogenesis inhibition; Springer Berlin Heidelberg, 2010; Vol. 180, pp 137-163.
101. Korpanty, G.; Huang, X.; Brekken, R. A. In The oncogenomics handbook; Humana Press, 2005, pp 415-428.
102. Giavazzi, R.; Bonezzi, K.; Taraboletti, G. In The role of microtubules in cell biology, neurobiology, and oncology; Humana press, 2008, pp 519-530.
103. Tozer, G. M.; Kanthou, C.; Chaplin, D. J. In Tumor angiogenesis; pringer Berlin Heidelberg, 2008, pp 809-829.